FinancialContent is the trusted provider of stock market information to the media industry.
February 07, 2012 at 08:20 AM EST
Biotech Sector Shows No Signs of Slowing -- OXiGENE and Generex Poised for Growth
The Paragon Report Provides Equity Research on OXiGENE & Generex Biotechnology

NEW YORK, NY -- (Marketwire) -- 02/07/12 -- Biotech stocks are on fire in 2012. The iShares NASDAQ Biotechnology index is up more than 15 percent year-to-date as impressive earnings results have boosted investor optimism in the industry. According to BB Biotech, "neither the government debt crisis nor recessionary pressures nor all the turmoil on the currency front" have been able to slow the biotech sector. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on OXiGENE, Inc. (NASDAQ: OXGN) and Generex Biotechnology Corporation (OTCBB: GNBT). Access to the full company reports can be found at:

www.paragonreport.com/OXGN
www.paragonreport.com/GNBT

BB Biotech says that the expected news flow from biotech pipelines in 2012 "also bodes well" for the industry in the current year. In 2011, regulators approved 13 new biotech products and major R&D milestones were reached all while the industry's revenues and profits exceeded market expectations, BB observes.

Global Industry Analysts, Inc. (GIA) says that improving economic conditions have led to an increase in funding for the biotechnology industry. GIA predicts that the global market for biotechnology will surpass $320 billion by 2015 thanks to increased availability of funding for R&D.

The Paragon Report provides investors with an excellent first step in their due diligence by providing daily trading ideas, and consolidating the public information available on them. For more investment research on the biotechnology industry register with us free at www.paragonreport.com and get exclusive access to our numerous stock reports and industry newsletters.

OXiGENE is a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases. The Company's major focus is developing vascular disrupting agents that selectively disrupt abnormal blood vessels associated with solid tumor progression and visual impairment.

Generex, the parent company of Antigen Express, is also engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs).

The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at http://www.paragonreport.com/disclaimer

Add to Digg Bookmark with del.icio.us Add to Newsvine

Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here
   
Financial Widgets

Display market data, financial news or stock quotes - Learn More

Advertising Network

Advertise on FinancialContent's huge network - Learn More

Web Services

Power your internet and wireless applications - Learn More